Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that its subsidiary, Novalere, Inc., has launched its product line into the hemp-derived, cannabinoid (“CBD”) oil-based products with the introduction of MZS Sleeping Aid™, a dietary supplement in tincture form delivering a 3 mg dose of melatonin per serving that incorporates either a 100 or 250 mg of hemp-derived CBD oil.
The company’s first investment will be in Bluhen Botanicals, purchasing a 50.1 percent stake for some US$30.6 million.
“We are launching Heavenly Rx with the aim of acquiring a portfolio of battle-tested and proven hemp/CBD companies while also acquiring certain unique brands for which we believe CBD and hemp-infused products could drastically change their growth,” added SOL’s chief investment officer Andy DeFrancesco. “We are more bullish than ever about the future of the hemp and CBD industries globally, and Heavenly Rx will without a doubt be the vertically integrated leader in the space. Heavenly Rx is not simply an investment company, but rather a laser-focused global Hemp and CBD company only for all operations under the Heavenly Rx banner.”
Seattle Washington Marijuana Flower awards.
Seattle Terpene Festival awards 2019
CBD DREAM takes First Place Award for the“Best CBD Flower”
Blowing Studio, Millennium Green won the 2019 First Place Award for the “Best CBD Flower”
with our Ringo’s Gift for the fruity aroma and another 2019 First Place Award for the “Best
THC & CBD Flower” with our trademark CBD DREAM. Ringo’s Gift had the highest CBD
potency and CBD DREAM had the best blend of THC/CBD and for its floral aroma. There were
160 entries. We won 2 of the 12 awards for flowers. Most of the winners were big players and
we were right up there in the big league with them. We now are consistently producing award
winning flowers and getting recognition as one of the best producers.
Folium… CBD manufacturer buys Andrews Foodservice building
In purchasing the Andrews Foodservice building, Folium Biosciences’ operation will operate in a building that is already an FDA-registered facility. That is key to the company’s future growth, which includes CBD-based food and drinks, CEO Kashif Shan said.
“With our industry rapidly pivoting toward mainstream food and beverage markets, purchasing an FDA registered facility made complete sense,” Shan said. “Five years of experience in this space has led us to identify the proper partnerships, equipment, and systems to execute with efficiency and optimum output.”
Spring Hope, NC, Feb. 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with bi-coastal processing centers including the 85,000 square-foot multipurpose industrial hemp processing facility in Spring Hope, North Carolina, a state of the art processing center in Medford, Oregon, and a 500-acre hemp growing Eco-Village in Golden Valley, Arizona, announced today that the Company has agreed upon a stock share with Gunpowder Capital Corporation, a Canadian merchant bank and advisory services firm.
1. Grow industrial hemp without fear of criminal prosecution;
2. Sell the entire industrial hemp plant or parts of the plant to anyone;
3. Process the plant as permitted by DATCP’s rules and regulations, which includes producing CBD. It is important to note that the legal protections under DATCP’s program discussed above apply only to farmers who are working in compliance with DATCP authorization and retailers who are selling CBD certified to be in compliance with the provisions of the Farm Bill. Rogue producers and retailers will still be subject to prosecution.
AUGUST 01, 2018
Take a look back once again to what schedule 5 classification could mean.
On June 25, the FDA approved London-based GW Pharmaceutical’s Epidiolex, a drug containing CBD as its active ingredient, to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years old and older. On the surface, that may seem like a victory for medical marijuana advocacy but, in reality, it only further muddies the legal status of CBD. In accordance with the Federal Food, Drug and Cosmetic Act, the FDA considers any product for human consumption containing the active ingredient (e.g., CBD) of an FDA-approved pharmaceutical drug (e.g., Epidiolex) “adulterated and misbranded,” according to a Q&A posted on the FDA website.
SUMMARY: With the issuance of this final order, the Acting Administrator of the Drug Enforcement Administration places certain drug products that have been approved by the Food and Drug Administration (FDA) and which contain cannabidiol (CBD) in schedule V of the Controlled Substances Act (CSA). Specifically, this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinol in schedule V. This action is required to satisfy the responsibility of the Acting Administrator under the CSA to place a drug in the schedule he deems most appropriate to carry out United States obligations under the Single Convention on Narcotic Drugs, 1961. Also consistent therewith, DEA is adding such drugs to the list of substances that may only be imported or exported pursuant to a permit. DATES: Effective [INSERT DATE OF PUBLICATION IN THE FEDERAL
The DEA said the new scheduling applies to “FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1% tetrahydrocannabinols.” So even though Epidiolex is the only formulation that currently meets the definition, the change could eventually affect other CBD formulations.
It’s still not legal to make CBD in the U.S. The DEA said “the bulk cannabis material used to make the Epidiolex formulation (as opposed to the FDA-approved drug product in finished dosage form) will remain in Schedule 1.”
At one point, he pressed the chairman and CEO of AbbVie, maker of the arthritis drug Humira, which, according to a recent New York Times story, has doubled in list price since 2012, from about $19,000 a year to $38,000. Wyden wanted to know whether the company makes money on drugs in Germany and other Westernized nations where patients pay, on average, 40% less than Americans.
Hello- I’m looking for a manufacturer of nutraceuticals products. Specifically for nutritional bars and powders. I have my own recipe but I’m open to private labeling. I’ve found several reputable companies but since they need to follow FDA guidelines they refuse to work with CBD. Any guidance is appreciated.
We have 16,000lbs a month of open tolling capacity in Colorado. We are open to paid tolling or splits(preferred paid). As of right now we can run into crude and distillate and will have Isolate capabilities in about 3 weeks.